Clinical Trial Update: Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD) [Phase 2]

View source ↗

Summary

Phase 2 study of FSD201 for chronic pain associated with idiopathic mast cell activation syndrome (MCAS/MCAD) was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Mast Cell Activation Disorder
• Mast Cell Activation Syndrome

Drugs mentioned

• FSD201

Snippet

Sponsor: Quantum Biopharma | Conditions: Mast Cell Activation Syndrome, Mast Cell Activation Disorder Idiopathic | Phase 2 | Status: TERMINATED | Results posted: 2026-04-21